---
title: "Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: References"
description: "Reference list for the formulary evidence report on Lirafugratinib (Lyrfigtu, RLY-4008) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma. 160 cited documents."
canonical: "https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/references"
published: "2026-09-27T09:44:05-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: References

<a id="references"></a>

## 5 References

1. [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/)
2. [Abou-Alfa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9512879/)
3. [Abou-Alfa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13015651/)
4. [American Cancer Society Key Statistics for Bile Duct Cancer (2024)](https://www.cancer.org/cancer/types/bile-duct-cancer/about/key-statistics.html)
5. [Anderson et al. (2023)](https://www.ispor.org/docs/default-source/intl2023/ispor23andersonposter126463-pdf.pdf)
6. [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/)
7. [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/)
8. [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)
9. [Beal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796337/)
10. [Benson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40930144/)
11. [Bilir et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5004818/)
12. [Borad et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4009)
13. [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)
14. [Buckarma et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35718679/)
15. [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)
16. [CADTH pemigatinib pharmacoeconomic review (2022)](https://www.ncbi.nlm.nih.gov/books/NBK603637/)
17. [CADTH pemigatinib reimbursement recommendation (2022)](https://www.ncbi.nlm.nih.gov/books/NBK599020/)
18. [CDA-AMC pemigatinib reimbursement recommendation (2025)](https://www.ncbi.nlm.nih.gov/books/NBK616196/)
19. [Chamberlain et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8107622/)
20. [Chen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10496386/)
21. [Chen et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11110281/)
22. [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)
23. [Chueh et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36575331/)
24. [ClinicalTrials.gov NCT04526106](https://clinicaltrials.gov/study/NCT04526106)
25. [ClinicalTrials.gov NCT07359820](https://clinicaltrials.gov/study/NCT07359820)
26. [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)
27. [Cristinziano et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33741397/)
28. [Ding et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12293483/)
29. [DiPeri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11900356/)
30. [Duff et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12128935/)
31. [Elevar Care Connect (2026)](https://elevarcareconnect.com/)
32. [Elevar Therapeutics and Relay Therapeutics licensing announcement (2024)](https://elevartx.com/2024/12/03/elevar-therapeutics-relay-therapeutics-licensing-agreement/)
33. [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)
34. [Elevar Therapeutics brand name announcement (2026)](https://elevartx.com/2026/09/22/elevar-conditional-acceptance-lyrfigtu/)
35. [Elevar Therapeutics EMA submission announcement (2026)](https://elevartx.com/2026/09/15/elevar-ema-authorization-application-1/)
36. [Elevar Therapeutics ESMO 2026 abstracts announcement (2026)](https://elevartx.com/2026/07/27/elevar-esmo-abstracts/)
37. [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)
38. [Elevar Therapeutics LYRFIGTU website](https://lyrfigtu.com/)
39. [Elevar Therapeutics NCCN Guidelines announcement (2026)](https://elevartx.com/2026/11/03/elevar-lyrfigtu-nccn-guidelines/)
40. [Elevar Therapeutics NDA submission announcement (2026)](https://elevartx.com/2026/01/28/elevar-therapeutics-new-drug-application-lirafugratinib/)
41. [Elevar Therapeutics priority review announcement (2026)](https://elevartx.com/2026/03/30/elevar-fda-acceptance-lira/)
42. [Elevar Therapeutics ReFocus202 first patient announcement (2026)](https://elevartx.com/2026/06/22/elevar-first-patient-dosed-lira/)
43. [Ellis et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41571046/)
44. [Facchinetti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7616615/)
45. [Facchinetti et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080319/)
46. [FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics guidance (2018)](https://www.fda.gov/media/71195/download)
47. [FDA Federal Register notice (2024)](https://www.federalregister.gov/documents/2024/05/16/2024-10714/helsinn-healthcare-sa-withdrawal-of-approval-of-new-drug-application-for-truseltiq-infigratinib)
48. [FDA futibatinib multi-discipline review (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf)
49. [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)
50. [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf)
51. [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)
52. [FDA Ongoing Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)
53. [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf)
54. [FDA TRUSELTIQ prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf)
55. [FDA Withdrawn Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)
56. [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/)
57. [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/)
58. [Giuliani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41519633/)
59. [Goldstein et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4737857/)
60. [González-Medina et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443220/)
61. [Goyal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5433349/)
62. [Goyal et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6677584/)
63. [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)
64. [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)
65. [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/)
66. [Hollebecque et al. (2022)](https://www.annalsofoncology.org/article/S0923-7534(22)03884-4/fulltext)
67. [Hollebecque et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.476)
68. [Hollebecque et al. (2026b)](https://elevartx.com/wp-content/uploads/2026/02/Hollebecque-et-al_ASCO-GI-2026-Lira-CCA-Oral-Presentation_7JAN2026_clean_FINAL.pdf)
69. [ICER Reference Case (2025)](https://icer.org/wp-content/uploads/2024/02/Reference-Case-4.3.25.pdf)
70. [Incyte Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm)
71. [Israel et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8417854/)
72. [Jain et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/35135097/)
73. [Javle et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34358484/)
74. [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)
75. [Javle et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41349554/)
76. [Kasi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10870120/)
77. [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)
78. [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)
79. [Kim et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS4251)
80. [Kim et al. (2026b)](https://elevartx.com/wp-content/uploads/2026/06/Kim-et-al_ELE-4008-202-ASCO-2026-TiP_v06.pdf)
81. [Korea Biomedical Review HLB pricing report (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=33516)
82. [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)
83. [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)
84. [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11840543/)
85. [Liguori et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396969/)
86. [Liu et al. (2022)](https://www.beonemedinfo.com/CongressDocuments/Liu_BGB-3111_BIM_WM_ISPOR_Poster_2022.pdf)
87. [Lowery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6642361/)
88. [Mahipal et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e16262)
89. [Mahipal et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.4109)
90. [McGregor et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9847521/)
91. [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/)
92. [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)
93. [Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9896158/)
94. [NICE TA1005 committee discussion (2024)](https://www.nice.org.uk/guidance/ta1005/chapter/3-Committee-discussion)
95. [NICE TA1005 information about futibatinib (2024)](https://www.nice.org.uk/guidance/ta1005/chapter/2-Information-about-futibatinib)
96. [NICE TA1005 recommendation (2024)](https://www.nice.org.uk/guidance/ta1005/chapter/1-Recommendation)
97. [NICE TA1005 resource impact summary report (2024)](https://www.nice.org.uk/guidance/ta1005/resources/resource-impact-summary-report-13544713693)
98. [NICE TA1153 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1153/chapter/3-Committee-discussion)
99. [NICE TA1153 recommendation (2026)](https://www.nice.org.uk/guidance/ta1153/chapter/1-Recommendations)
100. [NICE TA722 committee discussion (2021)](https://www.nice.org.uk/guidance/ta722/chapter/3-Committee-discussion)
101. [NICE TA722 information about pemigatinib (2021)](https://www.nice.org.uk/guidance/ta722/chapter/2-Information-about-pemigatinib)
102. [NICE TA722 recommendation (2021)](https://www.nice.org.uk/guidance/ta722/chapter/1-Recommendations)
103. [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)
104. [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/)
105. [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)
106. [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)
107. [Relay Therapeutics dose escalation data announcement (2023)](https://www.sec.gov/Archives/edgar/data/1812364/000095017023024290/rlay-ex99_1.htm)
108. [Relay Therapeutics ESMO 2022 data announcement (2022)](https://www.sec.gov/Archives/edgar/data/1812364/000095017022018311/rlay-ex99_1.htm)
109. [Relay Therapeutics Form 10-K (2024)](https://www.sec.gov/Archives/edgar/data/1812364/000095017024018797/rlay-20231231.htm)
110. [Relay Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1812364/000095017025027756/rlay-20241231.htm)
111. [Relay Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/rlay-20251231.htm)
112. [Relay Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338056/rlay-20260630.htm)
113. [Relay Therapeutics Form 8-K (2023)](https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/rlay-20231012.htm)
114. [Relay Therapeutics tumor-agnostic data announcement (2023)](https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/rlay-ex99_1.htm)
115. [Rocha-Gomes et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13360021/)
116. [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/)
117. [Rousian et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42331230/)
118. [Saverno et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11783287/)
119. [Schönherr et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10861881/)
120. [Schram et al. (2021)](https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS4165)
121. [Schram et al. (2023)](https://aacrjournals.org/mct/article/22/12_Supplement/IA006/730765/Abstract-IA006-Clinical-activity-of-lirafugratinib)
122. [Schram et al. (2026)](https://elevartx.com/wp-content/uploads/2026/06/Schram-et-al_AACR-Lira-poster-31Mar2026.pdf)
123. [Schultz et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391103/)
124. [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)
125. [Shroff et al. (2022)](https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.391)
126. [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)
127. [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/)
128. [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)
129. [Spencer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10323903/)
130. [Spira et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13189261/)
131. [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)
132. [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)
133. [Tai et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5470648/)
134. [Tzanetakos et al. (2023)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3784/130882)
135. [Van Dyke et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6467796/)
136. [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)
137. [Verma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13129466/)
138. [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)
139. [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)
140. [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/)
141. [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/)
142. [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)
143. [Wang et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11399825/)
144. [Wang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990505/)
145. [Wei et al. (2026)](https://elevartx.com/wp-content/uploads/2026/09/Wei-et-al-ASCPT-Lira-poster-20FEB2026.pdf)
146. [Winfree et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24winfreeee471poster136236-pdf.pdf?sfvrsn=9aa5e35d_0)
147. [Wu et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3694764/)
148. [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10767308/)
149. [Wu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41831281/)
150. [Xie et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12375827/)
151. [Xin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12897249/)
152. [Ye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9950513/)
153. [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)
154. [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/)
155. [Yoo et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40154623/)
156. [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)
157. [Yorio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11515446/)
158. [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12647265/)
159. [Zhang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12826477/)
160. [Zheng-Lin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13350865/)

## Related pages
- [Lirafugratinib (Lyrfigtu): Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Terms and abbreviations](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/terms-and-abbreviations.md)
- [Lirafugratinib (Lyrfigtu): Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/executive-summary.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Product information and disease description](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/product-information-and-disease-description.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Clinical evidence](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/clinical-evidence.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Economic information and modeling report](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/economics) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/economics.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: new drug review](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/monograph/review) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/monograph/review.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: prevalence by geography](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/prevalence) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/prevalence.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/cost-effectiveness-analyses.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: interactive budget impact model](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/budget-impact-model) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/budget-impact-model.md)
